ClinicalTrials.gg
TerminatedNCT01858532SONARUpdated Apr 24, 2019Results posted

Study Of Diabetic Nephropathy With Atrasentan

A Phase 3 interventional study of Atrasentan and Placebo in Diabetic Nephropathy, sponsored by AbbVie. Terminated. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-04-24.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Why this study was terminated
Strategic considerations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,107
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The study objective was to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine (DBSC) or the onset of end-stage renal disease (ESRD) in participants with type 2 diabetes and nephropathy who were treated with the maximum tolerated labeled daily dose (MTLDD) of a renin-angiotensin system (RAS) inhibitor. In addition, the study assessed the effects of atrasentan compared with placebo on cardiovascular (CV) morbidity and mortality, urine albumin excretion, changes in estimated glomerular filtration rate (eGFR), as well as the impact on quality of life in participants with type 2 diabetes and nephropathy.

Read the detailed description

This was a Phase 3, prospective, randomized, double-blind, enriched-population, placebo controlled, multicenter study in adult participants with type 2 diabetes and nephropathy. Participants who met the inclusion criteria for initial study entry and none of the exclusion criteria were eligible to proceed to the Run-In Period to optimize RAS inhibitor and diuretic doses. Following the Run-In Period, eligible participants entered the 6-week Enrichment Period in which all received atrasentan to determine their urinary albumin to creatinine ratio (UACR) response and to assess tolerability of atrasentan. Responders and nonresponders were then randomly assigned to receive atrasentan or placebo in the Double-Blind Treatment Period. The study was performed in 5 to 6 periods in the following sequence: Pre-Screening Period (optional); Screening Period (Visits S1 and S2); Run-In Period (up to 12 weeks; Visits R1 to R6); Enrichment Period (6 weeks; Visits E1 to E5); Double-Blind Treatment Period (randomization to final treatment visit); and Follow-Up Period (Final Treatment to F1 visit [45 days post treatment] and other post-treatment visits). The study was prematurely discontinued because of a lower than expected event rate for the renal composite endpoint, which was adjudicated by a blinded independent events adjudication committee (EAC).

02

Conditions studied

  • Diabetic Nephropathy

Keywords

  • Diabetes
  • Nephropathy
03

In context

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

This study's enrollment of 5,107 is above the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.

Browse Diabetic Nephropathies studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant, or legal representative, had voluntarily signed and dated an Form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study had been explained and the participant had the opportunity to ask questions. The informed consent must have been signed before any study-specific procedures were performed.
  • Participant had type 2 diabetes (including participants with latent diabetes or insulin-treated participants without a history of diabetic ketoacidosis who also had a negative anti-glutamic acid decarboxylase test AND an elevated post-prandial serum C-peptide level) and had been treated with at least one anti-hyperglycemic medication and an angiotensin-converting enzyme inhibitor (ACEi) or Angiotensin II receptor blocker (ARB; RAS inhibitor) for at least 4 weeks prior to the Screening S2 visit.
  • For entry into the Run-In Period the participant must have satisfied the following criteria based on the Screening laboratory values:

    • Estimated (eGFR) 25 to 75 mL/min/1.73 m\^2 [until the eGFR cap on participants (approximately 300) with a baseline of > 60 mL/min/1.73 m\^2 was reached] and a urine albumin creatinine ratio (UACR) greater than or equal to 300 and less than 5,000 mg/g (greater than or equal to 34 mg/mmol and less than 565 mg/mmol);
    • Serum albumin greater than or equal to 2.5 g/dL (25 g/L);
    • Brain natriuretic peptide (BNP) less than or equal to 200 pg/mL (200 ng/L);
    • Systolic blood pressure (SBP) greater than or equal to 110 and less than or equal to 180 mmHg;
    • Serum potassium greater than or equal to 3.5 mEq/L (3.5 mmol/L) and less than or equal to 6.0 mEq/L (6.0 mmol/L);
    • Participants on a maximum tolerated labeled daily dose (MTLDD) of a RAS inhibitor for greater than or equal to 4 weeks and on a diuretic at the time of screening and who satisfied the above criteria may have proceeded to the last visit in the Run-In Period (R6);
    • Participants already on a MTLDD of a RAS inhibitor for greater than or equal to 4 weeks and not on a diuretic (unless medically ) at the time of Screening were to start with a diuretic and participate in Run-In for at least 2 weeks.
  • For entry into the Enrichment Period the participant must have satisfied the following criteria based on the last visit of the Run-In Period:

    • RAS inhibitor at the MTLDD for the previous 4 weeks with no adjustments of the dose;
    • Participants that were on a MTLDD RAS inhibitor and not on a diuretic (unless medically contraindicated) at the time of Screening must have been in Run-In for at least 2 weeks.
  • For entry into the Double-Blind Treatment Period, participants must have satisfied the following criteria based on the last visit of the Enrichment Period:

    • RAS inhibitor at the MTLDD for the previous 6 weeks during the Enrichment Period with no adjustments of the dose;
    • Diuretic at any dose unless medically contraindicated or clinically intolerable in the investigator's judgement (i.e., hypotension or hypokalemia);
    • Participants must not have had a weight change greater than or equal to 3 kg from the beginning of Enrichment to the end of the Enrichment Period and absolute serum BNP greater than or equal to 300 pg/mL (300 ng/L) at the last Enrichment visit;
    • Participants must not have had an increase in serum creatinine greater than 0.5 mg/dL and greater than 20% increase from the beginning of Enrichment to the end of the Enrichment Period.

Exclusion criteria

Exclusion Criteria:

A participant was not eligible for entry into the Run-in Period if he/she met any of the following criteria:

  • Participant had a history of severe peripheral edema or facial edema requiring diuretics unrelated to trauma or a history of myxedema in the prior 4 weeks to the initial Screening S1 visit.
  • Participant had a history of pulmonary hypertension, pulmonary fibrosis or any lung diseases requiring oxygen therapy (e.g., , emphysema).
  • Participant had a documented diagnosis of heart failure, previous hospitalization for heart failure or current or constellation of symptoms (dyspnea on exertion, pedal edema, orthopnea, paroxysmal nocturnal dyspnea) felt to be compatible with heart failure, that was not explained by other causes, and for which there was a change in medication or other management directed at heart failure.
  • Participant had known non-diabetic kidney disease (other than kidney stones).
  • Participant had elevated liver enzymes (serum [ALT] and/or serum aspartate aminotransaminase [AST]) > 3 × the (ULN).
  • Participant had \< 9 g/dL (90 g/L).
  • Participant had a sensitivity to loop diuretics.
  • Participant had a history of an allergic reaction or significant sensitivity to atrasentan (or its ) or similar compounds.
  • Participant had a history of chronic gastrointestinal disease, which, in the Investigator's opinion, may have caused significant GI malabsorption.
  • Participant had a history of secondary hypertension (i.e., hemodynamically significant renal artery stenosis, primary aldosteronism or pheochromocytoma).
  • Participant had significant comorbidities (e.g., advanced , advanced liver disease) with a of less than 1 year.
  • Participant had cerebrovascular disease (CVD) or coronary artery disease (CAD) within 3 months prior to the Screening S1 visit, defined as one of the following:

    • Hospitalization for MI or unstable angina; or
    • New onset angina with positive functional study or coronary angiogram revealing stenosis; or
    • Coronary revascularization procedure; or
    • or Stroke.
  • Participant had received any drug including atrasentan within 3 months prior to the Screening S1 visit.
  • Participant received dialysis treatments or was expected to receive dialysis or renal transplant within 6 months of screening.
  • Participant was currently receiving rosiglitazone, moxonidine, aldosterone blockers, aliskiren or a combination of ACEi and ARB.
  • Participant was a premenopausal woman defined as (for study purposes) any female subject with a menses in the past 2 years. For women who were \< 50 years old, serum FSH must have been greater than 35 IU/L. Women who were surgically sterile or had a history of hysterectomy may not have necessarily be , and must also have had an FSH > 35 IU/L.
  • Participant was at high risk for /QTc prolongation such as a family history of Long QT Syndrome, defined as QTc prolongation exceeding 450 ms in men, or 460 ms in women.
  • Participant had type 1 diabetes.
  • Participant was considered to be clinically unstable regarding general, metabolic or cardiovascular health as determined by the Investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5,107 participants (actual)

Study arms

  • Active comparator
    Atrasentan

    0.75 mg atrasentan once daily by mouth for up to 52 months

    Drug: Atrasentan

  • Placebo comparator
    Placebo

    Placebo once daily by mouth for up to 52 months

    Drug: Placebo

Interventions

  • Film-coated tablet

    Also known as: ABT-627

  • DrugPlacebo

    Film-coated tablet

06

What researchers measure

Primary outcomes

  1. Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)

    Time to the first occurrence of a component of the composite renal endpoint was defined as doubling of serum creatinine (confirmed by a 30-day serum creatinine measurement) or the onset of end stage renal disease (estimated glomerular filtration rate \[eGFR\] less than 15 ml/min/1.73 m\^2 confirmed by a 90-day eGFR measurement, receiving chronic dialysis, renal transplantation, or renal death). Only events adjudicated by the Events Adjudication Committee (EAC) were considered in defining this endpoint. Data are presented as number of participants with a primary renal composite event (first event per participant).

    Time frame: From randomization to individual end of observation, up to 53 months

Secondary outcomes

  1. Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized)

    The event of interest for this outcome was a 50% reduction in a participant's estimated glomerular filtration rate (eGFR) value as compared to baseline, confirmed by a repeated value at least 20 days apart. The event time was defined as the first time that a 50% reduction in eGFR was observed. Data are presented as number of participants with a 50% reduction in eGFR (first event per participant).

    Time frame: From randomization to individual end of observation, up to 53 months

  2. Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)

    The composite event of interest for this outcome consisted of doubling of serum creatinine, end-stage renal disease (ESRD), cardiovascular (CV) death (including CV death and presumed CV death), nonfatal myocardial infarction (MI; heart attack) and nonfatal stroke. Presumed sudden cardiac death was included as a subcategory of presumed CV death. Only events adjudicated by the Events Adjudication Committee (EAC) were considered in defining this endpoint. Data are presented as number of participants with a cardio-renal composite event (first event per participant).

    Time frame: From randomization to individual end of observation, up to 53 months

  3. Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled)

    Time to the first occurrence of a component of the composite renal endpoint was defined as doubling of serum creatinine (confirmed by a 30-day serum creatinine measurement) or the onset of end stage renal disease (estimated glomerular filtration rate \[eGFR\] less than 15 ml/min/1.73 m\^2 confirmed by a 90-day eGFR measurement, receiving chronic dialysis, renal transplantation, or renal death). Data for all randomized participants were pooled by treatment and analyzed. Data are presented as number of participants with a renal composite event (first event per participant).

    Time frame: From randomization to individual end of observation, up to 53 months

  4. Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)

    The composite event of interest for this outcome was cardiovascular (CV) death (CV death, presumed CV death), nonfatal myocardial infarction (MI; heart attack), and nonfatal stroke. Presumed sudden cardiac death was included as a sub-category of presumed CV death. Only events adjudicated by the Events Adjudication Committee (EAC) were used. Data are presented as number of participants with a cardiovascular composite event (first event per participant).

    Time frame: From randomization to individual end of observation, up to 53 months

07

Results

Posted Apr 24, 2019

Participant flow

Participant flow — Overall Study
MilestoneIntent-to-Treat (ITT) Responder AtrasentanIntent-to-Treat (ITT) Responder PlaceboIntent-to-Treat (ITT) Non-responder AtrasentanIntent-to-Treat (ITT) Non-responder Placebo
Started13251323509511
Completed11441131411418
Not completed1811929893
Withdrew: Adverse event58502328
Withdrew: Withdrew consent71934627
Withdrew: Lost to follow-up17261114
Withdrew: Deterioration of medical status3437
Withdrew: Investigator request3426
Withdrew: Other, not specified29151311

Outcome measures

PrimaryTime to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)

Time to the first occurrence of a component of the composite renal endpoint was defined as doubling of serum creatinine (confirmed by a 30-day serum creatinine measurement) or the onset of end stage renal disease (estimated glomerular filtration rate \[eGFR\] less than 15 ml/min/1.73 m\^2 confirmed by a 90-day eGFR measurement, receiving chronic dialysis, renal transplantation, or renal death). Only events adjudicated by the Events Adjudication Committee (EAC) were considered in defining this endpoint. Data are presented as number of participants with a primary renal composite event (first event per participant).

Time frame:
From randomization to individual end of observation, up to 53 months
Reported as:
Count of participants · Participants
Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)
ParticipantsIntent-to-Treat (ITT) Responder AtrasentanIntent-to-Treat (ITT) Responder Placebo
Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)79105
Statistical analysis
  • Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo · Stratified log-rank test · p = =0.029
  • Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo · Regression, Cox · p = =0.005 · Hazard ratio (hr): 0.654 · 95% CI 0.488 to 0.878
SecondaryTime to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized)

The event of interest for this outcome was a 50% reduction in a participant's estimated glomerular filtration rate (eGFR) value as compared to baseline, confirmed by a repeated value at least 20 days apart. The event time was defined as the first time that a 50% reduction in eGFR was observed. Data are presented as number of participants with a 50% reduction in eGFR (first event per participant).

Time frame:
From randomization to individual end of observation, up to 53 months
Reported as:
Count of participants · Participants
Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized)
ParticipantsIntent-to-Treat (ITT) Responder AtrasentanIntent-to-Treat (ITT) Responder Placebo
Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized)7888
Statistical analysis
  • Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo · Stratified log-rank test · p = =0.289
  • Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo · Regression, Cox · p = 0.112 · Hazard ratio (hr): 0.779 · 95% CI 0.573 to 1.060
SecondaryTime to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)

The composite event of interest for this outcome consisted of doubling of serum creatinine, end-stage renal disease (ESRD), cardiovascular (CV) death (including CV death and presumed CV death), nonfatal myocardial infarction (MI; heart attack) and nonfatal stroke. Presumed sudden cardiac death was included as a subcategory of presumed CV death. Only events adjudicated by the Events Adjudication Committee (EAC) were considered in defining this endpoint. Data are presented as number of participants with a cardio-renal composite event (first event per participant).

Time frame:
From randomization to individual end of observation, up to 53 months
Reported as:
Count of participants · Participants
Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)
ParticipantsIntent-to-Treat (ITT) Responder AtrasentanIntent-to-Treat (ITT) Responder Placebo
Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)147172
Statistical analysis
  • Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo · Stratified log-rank test · p = 0.089
  • Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo · Regression, Cox · p = 0.049 · Hazard ratio (hr): 0.801 · 95% CI 0.642 to 0.999
SecondaryTime to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled)

Time to the first occurrence of a component of the composite renal endpoint was defined as doubling of serum creatinine (confirmed by a 30-day serum creatinine measurement) or the onset of end stage renal disease (estimated glomerular filtration rate \[eGFR\] less than 15 ml/min/1.73 m\^2 confirmed by a 90-day eGFR measurement, receiving chronic dialysis, renal transplantation, or renal death). Data for all randomized participants were pooled by treatment and analyzed. Data are presented as number of participants with a renal composite event (first event per participant).

Time frame:
From randomization to individual end of observation, up to 53 months
Reported as:
Count of participants · Participants
Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled)
ParticipantsIntent-to-Treat (ITT) AtrasentanIntent-to-Treat Placebo
Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled)152192
Statistical analysis
  • Intent-to-Treat (ITT) Atrasentan vs Intent-to-Treat Placebo · Regression, Cox · p = 0.002 · Hazard ratio (hr): 0.72 · 95% CI 0.58 to 0.89
SecondaryTime to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)

The composite event of interest for this outcome was cardiovascular (CV) death (CV death, presumed CV death), nonfatal myocardial infarction (MI; heart attack), and nonfatal stroke. Presumed sudden cardiac death was included as a sub-category of presumed CV death. Only events adjudicated by the Events Adjudication Committee (EAC) were used. Data are presented as number of participants with a cardiovascular composite event (first event per participant).

Time frame:
From randomization to individual end of observation, up to 53 months
Reported as:
Count of participants · Participants
Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)
ParticipantsIntent-to-Treat (ITT) Responder AtrasentanIntent-to-Treat (ITT) Responder Placebo
Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)7281
Statistical analysis
  • Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo · Stratified log-rank test · p = 0.446
  • Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo · Regression, Cox · p = 0.447 · Hazard ratio (hr): 0.884 · 95% CI 0.643 to 1.215

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were reported from the time of study drug administration until 45 days after the last dose of study drug (up to 24 weeks for the All Atrasentan Set in the Enrichment Period; up to 54 months for the ITT sets in the Double-Blind Period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enrichment Atrasentan25/5,107 (0.5%)292/5,107 (5.7%)1,781/5,107 (34.9%)
Double-Blind Atrasentan84/1,829 (4.6%)685/1,829 (37.5%)1,043/1,829 (57%)
Double-Blind Placebo79/1,830 (4.3%)626/1,830 (34.2%)1,038/1,830 (56.7%)
Most frequent serious events
Showing 10 of 787
Most frequent serious events
EventEnrichment AtrasentanDouble-Blind AtrasentanDouble-Blind Placebo
PNEUMONIAInfections and infestations14/510754/182941/1830
ACUTE KIDNEY INJURYRenal and urinary disorders19/510754/182936/1830
CARDIAC FAILURE CONGESTIVECardiac disorders22/510737/182922/1830
ACUTE MYOCARDIAL INFARCTIONCardiac disorders7/510734/182928/1830
CORONARY ARTERY DISEASECardiac disorders6/510729/182919/1830
ANAEMIABlood and lymphatic system disorders7/510727/182911/1830
END STAGE RENAL DISEASERenal and urinary disorders0/510719/182927/1830
HYPOGLYCAEMIAMetabolism and nutrition disorders13/510722/182912/1830
CELLULITISInfections and infestations5/510714/182922/1830
URINARY TRACT INFECTIONInfections and infestations6/510721/182912/1830
Most frequent other events
Showing 10 of 11
Most frequent other events
EventEnrichment AtrasentanDouble-Blind AtrasentanDouble-Blind Placebo
OEDEMA PERIPHERALGeneral disorders1148/5107534/1829483/1830
HYPERTENSIONVascular disorders78/5107158/1829218/1830
ANAEMIABlood and lymphatic system disorders180/5107216/1829127/1830
NASOPHARYNGITISInfections and infestations145/5107180/1829169/1830
HYPERKALAEMIAMetabolism and nutrition disorders77/5107132/1829143/1830
BACK PAINMusculoskeletal and connective tissue disorders61/510788/1829125/1830
HYPOGLYCAEMIAMetabolism and nutrition disorders126/5107114/1829120/1830
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations110/5107106/1829114/1830
HYPERURICAEMIAMetabolism and nutrition disorders84/5107101/1829105/1830
DIARRHOEAGastrointestinal disorders103/510799/1829103/1830

Baseline characteristics

Intent-to-Treat (ITT) Responders (participants who achieved at least 30% reduction in their albumin to creatinine ratio \[UACR\] in the Enrichment Period \[EP\]) and ITT Non-responders (Participants who achieved \< 30% reduction in their UACR in the EP)

Age, Continuous
Age, Continuous(years)Intent-to-Treat (ITT) Responder AtrasentanIntent-to-Treat (ITT) Responder PlaceboIntent-to-Treat (ITT) Non-responder AtrasentanIntent-to-Treat (ITT) Non-responder PlaceboTotal
Mean64.9 ± 8.6464.7 ± 8.6663.8 ± 9.1263.6 ± 8.9364.5 ± 8.77
Sex: Female, Male
Sex: Female, Male(Participants)Intent-to-Treat (ITT) Responder AtrasentanIntent-to-Treat (ITT) Responder PlaceboIntent-to-Treat (ITT) Non-responder AtrasentanIntent-to-Treat (ITT) Non-responder PlaceboTotal
Female331352127136946
Male9949713823752722
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intent-to-Treat (ITT) Responder AtrasentanIntent-to-Treat (ITT) Responder PlaceboIntent-to-Treat (ITT) Non-responder AtrasentanIntent-to-Treat (ITT) Non-responder PlaceboTotal
American Indian or Alaska Native302971076
Asian4464551431541198
Native Hawaiian or Other Pacific Islander997328
Black or African American73763639224
White7537443133002110
More than one race14103532
Unknown or Not Reported00000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Smeijer JD, Koomen J, Kohan DE, McMurray JJV, Bakris GL, Correa-Rotter R, Hou FF, Januzzi JL, Kitzman DW, Kolansky DM, Makino H, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. JACC Heart Fail. 2022 Jul;10(7):498-507. doi: 10.1016/j.jchf.2022.03.004. Epub 2022 May 4. PubMed 35772861 ↗
  • Waijer SW, Gansevoort RT, Bakris GL, Correa-Rotter R, Hou FF, Kohan DE, Kitzman DW, Makino H, McMurray JJV, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021 Dec;16(12):1824-1832. doi: 10.2215/CJN.07340521. Epub 2021 Dec 1. PubMed 34853062 ↗
  • Koomen JV, Stevens J, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan DE, Makino H, McMurray JJV, Parving HH, Perkovic V, Tobe SW, de Zeeuw D, Heerspink HJL. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 Jun;109(6):1631-1638. doi: 10.1002/cpt.2143. Epub 2021 Jan 5. PubMed 33338269 ↗
  • Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum In: Lancet. 2019 May 11;393(10184):1936. doi: 10.1016/S0140-6736(19)30939-0. PubMed 30995972 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Mar 2018, 58 months.

Results were first posted in Apr 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2013
First posted
May 21, 2013
StartActual
May 17, 2013
Primary completionActual
Mar 29, 2018
CompletionActual
Mar 29, 2018
Results first posted
Apr 24, 2019
Last update
Apr 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01858532
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 21, 2013
Start date
May 17, 2013
Primary completion
Mar 29, 2018
Completion
Mar 29, 2018
Results posted
Apr 24, 2019
Last update
Apr 24, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atrasentan

Start the discussion